Related Experiment Video
Updated: Mar 1, 2026
A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Nanomedicine for prostate cancer using nanoemulsion: A review
Aravindsiva Sasikumar1, Kaladhar Kamalasanan1
1Department of Pharmaceutics, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham University, Amrita University, AIMS Health Sciences Campus, Kochi, Kerala, India.
Abstract:
Prostate cancer (PCa) is a worldwide issue, with burgeoning rise in prevalence, morbidity and mortality. Targeted drug delivery, a long sort solution in this regard using controlled release (CR) - nanocarriers, is still a challenge. There is an emerging criticism that, the challenges are due to less appreciation for the biological barriers and lack of corresponding newer technologies. Over the years, more understanding about the biological barriers has come with the progress in characterization techniques. Correspondingly, there is a change in opinion about approaches in clinical trial that; focus of the end point need to be shifted towards disease stabilization for these explorative technologies. Currently, there is a requirement to overcome these newly identified challenges to develop newer affordable therapeutics. The ongoing clinical protocol for therapy using CR-nanocarriers is intravenous injection followed by local targeting to cancer site. This is the most accepted protocol and new CR-nanocarriers are being developed to suit this protocol. In this review, recent progress in treatment of PCa using CR-nanocarriers is analyzed with respect to newly identified biological barriers and design challenges. Possibilities of exploring nanoemulsion (NE) platform for targeted drug delivery to PCa are examined. Repurposing of drugs and combination therapy using NE platform targeted to PCa can be explored for design and development of affordable nanomedicine. In 20yrs. from now there expected to be numerous affordable nanomedicine technologies available in market exploring these lines.
Insights
Developing controlled release (CR) nanocarriers for prostate cancer (PCa) faces challenges due to biological barriers. This review analyzes CR-nanocarrier progress and explores nanoemulsion platforms for affordable PCa nanomedicine.
Area of Science:
- Oncology
- Nanotechnology
- Drug Delivery
Background:
- Prostate cancer (PCa) presents a growing global health challenge with increasing incidence, morbidity, and mortality.
- Targeted drug delivery using controlled release (CR) nanocarriers remains a significant hurdle in PCa treatment.
- Understanding biological barriers and developing novel technologies are crucial for effective nanocarrier-based therapies.
Purpose of the Study:
- To review recent advancements in treating PCa with CR-nanocarriers.
- To analyze design challenges and biological barriers impacting nanocarrier efficacy.
- To explore the potential of nanoemulsion (NE) platforms for targeted PCa drug delivery.
Main Methods:
- Analysis of current literature on CR-nanocarrier applications in PCa treatment.
- Examination of biological barriers and their impact on nanocarrier performance.
- Evaluation of nanoemulsion (NE) platforms for targeted drug delivery in PCa.
Main Results:
- Progress in understanding biological barriers has informed nanocarrier design.
- A shift in clinical trial focus towards disease stabilization is recommended for novel therapies.
- Nanoemulsion platforms show promise for targeted PCa drug delivery, potentially enabling repurposed drugs and combination therapies.
Conclusions:
- Overcoming identified biological barriers and design challenges is essential for developing effective and affordable PCa nanomedicines.
- Nanoemulsion platforms offer a viable strategy for targeted drug delivery in PCa.
- Future development of affordable nanomedicine technologies for PCa is anticipated within two decades.
